The British pharmaceutical company AstraZeneca has once again increased its sales forecast for 2019. This is partly because the company is growing strongly in China. The company also made good money from a number of anti-cancer drugs.

AstraZeneca now expects a revenue growth of between 10 percent and 15 percent. The pharmaceutical company previously estimated that the increase would not amount to more than 12 percent.

In the third quarter, AstraZeneca achieved revenues of $ 6.4 billion, an increase of 16 percent over the same reporting period a year earlier. The operating profit amounted to $ 757 million. That was a decrease of 11 percent and was partly due to higher legal provisions than a year earlier. A settlement a year earlier also contributed hundreds of millions of dollars to the result.